A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-01

Study Completion Date

2025-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To establish the antitumor activity and safety of the anti-programmed death 1 receptor monoclonal antibody, Treprilimab, in patients with local recurrent/residual nasopharyngeal carcinoma after re-irradiation.Patients with local recurrent/residual NPC after re-irradiation were treated with Treprilimab until disease progression or unacceptable toxicity. The primary end point was objective response rate (ORR) and secondary end points included survival and toxicity.The sample size of this study was estimated on the assumption that response rates (RRs) to Treprilimab should be around 25%,based on a report that was available at the time this study was planned.Furthermore, the RR to noncytotoxic, experimental agents such as pazopanib and cetuximab in similarly pretreated patient cohorts was approximately 5% to 10%. This study's design was based on the modiﬁed Simon two-stage optimal design (α=0.05，β=0.2,n1=2/22,n2=7/40). If two responses were observed during the ﬁrst stage, enrollment was continued until a total of 40 patients was reached.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.

NCT03854838

Nasopharyngeal Carcinoma Nasopharyngeal Neoplasms Nasopharyngeal Diseases +1 more

UNKNOWN PHASE2

Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma

NCT07110558

Nasopharyngeal Cancinoma (NPC)

NOT_YET_RECRUITING PHASE2

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

NCT04376866

Recurrent Nasopharyngeal Carcinoma

RECRUITING PHASE3

A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma

NCT04895345

Nasopharyngeal Carcinoma

COMPLETED PHASE2

Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma

NCT07135804

Locally Advanced Nasopharyngeal Squamous Cell Carcinoma

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To establish the antitumor activity and safety of the anti-programmed death 1 receptor monoclonal antibody, Treprilimab, in patients with local recurrent/residual nasopharyngeal carcinoma after re-irradiation.Patients with local recurrent/residual NPC after re-irradiation were treated with Treprilimab until disease progression or unacceptable toxicity. The primary end point was objective response rate (ORR) and secondary end points included survival and toxicity.The sample size of this study was estimated on the assumption that response rates (RRs) to Treprilimab should be around 25%,based on a report that was available at the time this study was planned.Furthermore, the RR to noncytotoxic, experimental agents such as pazopanib and cetuximab in similarly pretreated patient cohorts was approximately 5% to 10%. This study's design was based on the modiﬁed Simon two-stage optimal design (α=0.05，β=0.2,n1=2/22,n2=7/40). If two responses were observed during the ﬁrst stage, enrollment was continued until a total of 40 patients was reached. The target lesions had to be measurable by the Response Evaluation Criteria in Solid Tumors (RECIST). Radiologic assessments were performed every 8 weeks for 6 months and then every 12 weeks thereafter. Eligible patients were treated with Treprilimab at a dosage of 240mg intravenously every 3 weeks until they experienced disease progression or unacceptable toxicity. The primary end point of this study was objective response by the RECIST criteria , and the secondary end points were overall survival (OS), progression-free survival (PFS), duration of response and toxicity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasopharyngeal Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treprilimab treatment group

Treprilimab 240mg ivdrip Q3W until progression or unacceptable toxicity

Group Type EXPERIMENTAL

Treprilimab

Intervention Type DRUG

Treprilimab 240mg Q3W until progression or unacceptable toxicity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treprilimab

Treprilimab 240mg Q3W until progression or unacceptable toxicity

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ages from 18 years to 65 years.
* Histologically confirmed local recurrent/residual Nasopharyngeal carcinoma with previous re-irradiation.
* measurable disease at baseline on the basis of RECIST v1.1.
* Eastern Cooperative Oncology Group performance status of 0 or 1.
* adequate organ function.
* anticipate survival≥3 months.

Exclusion Criteria

* a diagnosis of immuno deﬁciency or systemic corticosteroid therapy within 14 days of study start.
* prior anticancer monoclonal antibody therapy within 4 weeks of study start.
* any anticancer therapy within 4 weeks preceding the study start.
* therapy with any other immune checkpoint inhibitor.
* active autoimmune disease, interstitial lung disease, known additional malignancy that was progressing or that required active treatment.
* not received platinum based chemotherapy previously.
* confirmed systemic metastasis
* HBV positive and Child-Pugh B or C cirrhosis
* HCV positive and Child-Pugh B or C cirrhosis

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No